Targeting Disseminated Estrogen-Receptor-Positive Breast Cancer Cells in Bone Marrow

Estrogen receptor-positive (ER+) breast cancer can recur up to 20 years after initial diagnosis. Delayed recurrences arise from disseminated tumors cells (DTCs) in sites such as bone marrow that remain quiescent during endocrine therapy and subsequently proliferate to produce clinically-detectable m...

Descripción completa

Detalles Bibliográficos
Autores principales: Buschhaus, Johanna M., Humphries, Brock A., Eckley, Samantha S., Robison, Tanner H., Cutter, Alyssa C., Rajendran, Shrila, Haley, Henry R., Bevoor, Avinash S., Luker, Kathryn E., Luker, Gary D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442734/
https://www.ncbi.nlm.nih.gov/pubmed/32678295
http://dx.doi.org/10.1038/s41388-020-01391-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442734/
https://www.ncbi.nlm.nih.gov/pubmed/32678295
http://dx.doi.org/10.1038/s41388-020-01391-z

Ejemplares similares